Genmab A (GMAB) Property, Plant & Equipment (Net) (2018 - 2026)
Powered by 
Analysis
Genmab A (GMAB) Property, Plant & Equipment (Net) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Property, Plant & Equipment (Net) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 8.55 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 5.83 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 1.67 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 5.46 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 2.06 Bn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 554.14 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 2.99 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 11.32 Mn |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | 137.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 137.00 Mn |
| Mar 31, 2026 | 143.00 Mn |
| Dec 31, 2025 | 153.00 Mn |
| Sep 30, 2025 | 212.27 Mn |
| Jun 30, 2025 | 152.00 Mn |
| Mar 31, 2025 | 9.99 Bn |
| Dec 31, 2024 | 87.18 Mn |
| Sep 30, 2024 | 2.40 Bn |
| Jun 30, 2024 | 89.12 Mn |
| Mar 31, 2024 | 90.31 Mn |
| Dec 31, 2023 | 89.72 Mn |
| Sep 30, 2023 | 209.00 Mn |
| Jun 30, 2023 | 86.36 Mn |
| Mar 31, 2023 | 2.16 Bn |
| Jan 1, 2023 | 115.00 Mn |
| Dec 31, 2022 | 2.43 Mn |
| Sep 30, 2022 | 184.99 Mn |
| Jun 30, 2022 | 69.73 Mn |
| Mar 31, 2022 | 67.75 Mn |
| Dec 31, 2021 | 345.09 Mn |